HFS
NTLA icon

Hughes Financial Services’s Intellia Therapeutics NTLA Stock Holding History

Hughes Financial Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-75
Closed -$730 – 1322
2025
Q3 		$730 Hold
75
– – ﹤0.01% 806
2025
Q2 		$853 Sell
75
-32
-30% -$263 ﹤0.01% 739
2025
Q1 		$712 Buy
+107
New +$1.08K ﹤0.01% 757

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hughes Financial Services's NTLA Position: Q4 2025 in Review

Hughes Financial Services sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 75 shares — an estimated $730 sold.

Hughes Financial Services first reported a position in NTLA in Q1 2025 and held it in 3 quarters. The position peaked at $853 in Q2 2025. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Hughes Financial Services reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Hughes Financial Services sold 75 Intellia Therapeutics shares in Q4 2025, an estimated $730.
  • Hughes Financial Services first reported a position in Intellia Therapeutics in Q1 2025 and held it in 3 quarters.
  • Hughes Financial Services's Intellia Therapeutics position peaked at $853 in Q2 2025.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Hughes Financial Services's 13F filing for Q4 2025, filed 11 Feb 2026.